You are here

Generic Bupropion HCl Sustained Release Tablets Launched

CORONA, Calif., Jan. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) , a leading specialty pharmaceutical company, announced today that, under a supply agreement with GlaxoSmithKline (GSK), the Company has initiated shipments of bupropion hydrochloride sustained-release tablets, in the 100mg strength. The product is the generic version of GlaxoSmithKline's Wellbutrin SR(R) which is indicated for the treatment of depression. For the 12-months ending November 2003, Wellbutrin SR(R) 100mg had sales of approximately $300 million, according to IMS data.

Under a previously announced settlement with GSK, Watson received rights in the United States (US) market to distribute 100mg and 150mg bupropion hydrochloride sustained-release tablets, manufactured by a GSK subsidiary, on a per strength basis, once a third party launches a fully substitutable generic equivalent of the relevant strength of these products in the US market. Watson currently has rights to ship only the 100mg strength of bupropion hydrochloride sustained-release tablets. GSK will receive a share of the profits from Watson's sales of generic bupropion hydrochloride sustained release tablets in the US market. Terms of the agreement were not disclosed.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels